BRPI0614867A2 - anticorpo quimérico ou uma porção de ligação de antìgeno do mesmo, método para produzir um anticorpo quimérico ou uma porção de ligação de antìgeno do mesmo, e, kit - Google Patents

anticorpo quimérico ou uma porção de ligação de antìgeno do mesmo, método para produzir um anticorpo quimérico ou uma porção de ligação de antìgeno do mesmo, e, kit Download PDF

Info

Publication number
BRPI0614867A2
BRPI0614867A2 BRPI0614867-0A BRPI0614867A BRPI0614867A2 BR PI0614867 A2 BRPI0614867 A2 BR PI0614867A2 BR PI0614867 A BRPI0614867 A BR PI0614867A BR PI0614867 A2 BRPI0614867 A2 BR PI0614867A2
Authority
BR
Brazil
Prior art keywords
thr
antigen binding
binding portion
ser
pro
Prior art date
Application number
BRPI0614867-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Philip Anthony Jennings
Anthony Gerard Doyle
Adam William Clarke
Original Assignee
Arana Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005904406A external-priority patent/AU2005904406A0/en
Application filed by Arana Therapeutics Ltd filed Critical Arana Therapeutics Ltd
Publication of BRPI0614867A2 publication Critical patent/BRPI0614867A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0614867-0A 2005-08-15 2006-08-15 anticorpo quimérico ou uma porção de ligação de antìgeno do mesmo, método para produzir um anticorpo quimérico ou uma porção de ligação de antìgeno do mesmo, e, kit BRPI0614867A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2005904406 2005-08-15
AU2005904406A AU2005904406A0 (en) 2005-08-15 New World Antibodies
PCT/AU2006/001166 WO2007019621A1 (en) 2005-08-15 2006-08-15 Chimeric antibodies with new world primate regions

Publications (1)

Publication Number Publication Date
BRPI0614867A2 true BRPI0614867A2 (pt) 2012-01-31

Family

ID=37757238

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0614430-6A BRPI0614430A2 (pt) 2005-08-15 2006-08-15 anticorpo ou uma porção de ligação de antìgeno do mesmo, e, kit
BRPI0614867-0A BRPI0614867A2 (pt) 2005-08-15 2006-08-15 anticorpo quimérico ou uma porção de ligação de antìgeno do mesmo, método para produzir um anticorpo quimérico ou uma porção de ligação de antìgeno do mesmo, e, kit

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0614430-6A BRPI0614430A2 (pt) 2005-08-15 2006-08-15 anticorpo ou uma porção de ligação de antìgeno do mesmo, e, kit

Country Status (13)

Country Link
EP (1) EP1945669A4 (de)
JP (1) JP2009504686A (de)
KR (1) KR20080068005A (de)
CN (2) CN101287763A (de)
AU (1) AU2006281981A1 (de)
BR (2) BRPI0614430A2 (de)
CA (1) CA2619245A1 (de)
MX (1) MX2008002161A (de)
NO (1) NO20080800L (de)
NZ (1) NZ565904A (de)
RU (1) RU2008110058A (de)
WO (1) WO2007019621A1 (de)
ZA (2) ZA200802246B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20070027A (en) 2004-07-26 2008-11-28 Biogen Idec Ma Inc., Anti-cd154 antibodies
KR20090039666A (ko) 2006-02-01 2009-04-22 아라나 테라퓨틱스 리미티드 도메인 항체 구조체
JP5721951B2 (ja) * 2007-03-22 2015-05-20 バイオジェン アイデック マサチューセッツ インコーポレイテッド 抗体、抗体誘導体、および抗体断片を含む、ｃｄ１５４に特異的に結合する結合タンパク質ならびにその使用
CA2733742A1 (en) * 2008-08-14 2010-02-18 Cephalon Australia Pty Ltd Variant domain antibodies
RU2535034C2 (ru) * 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
RU2517085C2 (ru) * 2010-08-06 2014-05-27 Олег Ильич Эпштейн Комплексное лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
RU2516931C2 (ru) * 2010-08-06 2014-05-20 Олег Ильич Эпштейн Способ и композиция для профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
RU2577299C2 (ru) * 2011-07-04 2016-03-10 Олег Ильич Эпштейн Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний
RU2519862C2 (ru) * 2010-08-06 2014-06-20 Олег Ильич Эпштейн Комплексное лекарственное средство и способ профилактики и лечения инфекционных вирусных заболеваний
RU2535033C2 (ru) * 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
RU2521392C2 (ru) * 2010-08-06 2014-06-27 Олег Ильич Эпштейн Комплексное лекарственное средство для лечения вирусных заболеваний и способ лечения вирусных заболеваний
RU2505312C2 (ru) * 2010-08-06 2014-01-27 Олег Ильич Эпштейн Комплексное лекарственное средство для лечения гриппа различных типов
RU2502521C2 (ru) * 2010-08-06 2013-12-27 Олег Ильич Эпштейн Комплексное лекарственное средство для лечения бактериальных инфекций и способ лечения бактериальных инфекций
RU2579262C1 (ru) * 2014-10-02 2016-04-10 Мапикс Эс.Эй.Ар.Эл. Лекарственное средство для лечения инфекционных заболеваний
CL2015002152A1 (es) * 2015-07-31 2016-06-03 Pontificia Universidad Católica De Chile Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnostico de la infección causada por vrsh

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0605442B1 (de) * 1991-07-25 2003-04-16 Idec Pharmaceuticals Corporation Rekombinante antikörper zur humanen therapie
US6569431B2 (en) * 2000-10-17 2003-05-27 The Regents Of The University Of California Recombinant antibody fragments as autoantibody antagonists
US7235643B2 (en) * 2000-11-07 2007-06-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with high affinity
EP2366718A3 (de) * 2002-06-28 2012-05-02 Domantis Limited Ligand
AU2004290016A1 (en) * 2003-11-07 2005-05-26 Amgen Inc. Monkey immunoglobulin sequences

Also Published As

Publication number Publication date
CA2619245A1 (en) 2007-02-22
ZA200802246B (en) 2009-09-30
ZA200802247B (en) 2009-08-26
NZ565904A (en) 2012-02-24
CN101287763A (zh) 2008-10-15
BRPI0614430A2 (pt) 2011-03-29
JP2009504686A (ja) 2009-02-05
WO2007019621A1 (en) 2007-02-22
EP1945669A4 (de) 2009-07-22
CN101287762A (zh) 2008-10-15
MX2008002161A (es) 2008-04-22
RU2008110058A (ru) 2009-09-27
AU2006281981A1 (en) 2007-02-22
KR20080068005A (ko) 2008-07-22
NO20080800L (no) 2008-05-09
EP1945669A1 (de) 2008-07-23

Similar Documents

Publication Publication Date Title
BRPI0614867A2 (pt) anticorpo quimérico ou uma porção de ligação de antìgeno do mesmo, método para produzir um anticorpo quimérico ou uma porção de ligação de antìgeno do mesmo, e, kit
US20080095767A1 (en) Engineered antibodies with new world primate framework regions
RU2765306C2 (ru) Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение
US7083784B2 (en) Molecules with extended half-lives, compositions and uses thereof
US20080255343A1 (en) Chimeric antibodies
JP5259423B2 (ja) ドメイン抗体構築物
US7981414B2 (en) Anti-inflammatory dAb
MXPA03000201A (es) Anticuerpos para mcp-1 humana.
JP2009525031A5 (de)
AU2014269287A1 (en) Anti-TNF-alpha/CXCL10 double-targeting antibody and use thereof
AU2021358662A1 (en) CD1a ANTIBODIES AND USES THEREOF
MX2008002162A (en) Engineered antibodies with new world primate framework regions
CN113166273A (zh) 具有il-7活性的双功能分子
BRPI0620115A2 (pt) anticorpo de domìnio recombinante, molécula de ácido nucleico isolada, composição farmacêutica, e, métodos para detectar o tnf-alfa humano em uma amostra e para tratar de um distúrbio distinguido pela atividade do tnf-alfa humano em um indivìduo humano
MX2008008029A (es) Dab antiinflamatorio

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ARANA THERAPEUTICS PTY LTD. (AU)

Free format text: NOME ALTERADO DE: ARANA THERAPEUTICS LIMITED

B25D Requested change of name of applicant approved

Owner name: CEPHALON AUSTRALIA PTY LTD. (AU)

Free format text: NOME ALTERADO DE: ARANA THERAPEUTICS PTY LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2214 DE 11/06/2013.